TLX301 (177Lu-DOTA-rituximab)

About Telix Pharmaceuticals

Telix Pharmaceuticals is a commercial-stage leader in the theranostic radiopharmaceutical space, with a mission to deliver precision medicine through targeted radiation. Its strategy is validated by the successful global commercialization of its FDA-approved prostate cancer imaging agent, Illuccix®, which funds and de-risks a broad, late-stage pipeline of therapeutic candidates. The company is executing a vertically integrated model, combining therapeutic development with precision diagnostics, medtech, and a global manufacturing network to capture value across the cancer care continuum.

Therapeutic Areas